These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 25457583)

  • 1. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis.
    Carrier M; Cameron C; Delluc A; Castellucci L; Khorana AA; Lee AY
    Thromb Res; 2014 Dec; 134(6):1214-9. PubMed ID: 25457583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
    Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
    Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
    Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
    Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis.
    Chen H; Tao R; Zhao H; Jiang J; Yang J
    Medicine (Baltimore); 2020 Jan; 99(5):e19000. PubMed ID: 32000440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
    Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
    Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Arthroscopic Surgery and Anterior Cruciate Ligament Reconstruction: A Meta-analysis of Randomized Controlled Trials.
    Zhu J; Jiang H; Marshall B; Li J; Tang X
    Am J Sports Med; 2019 Jul; 47(8):1994-2002. PubMed ID: 30113231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials.
    Brunetti ND; Tricarico L; Correale M; De Gennaro L; Santoro F; Ieva R; Di Biase M
    J Thromb Thrombolysis; 2020 Aug; 50(2):305-310. PubMed ID: 31654194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis.
    Dong Y; Wang Y; Ma RL; Liu M; Gao JZ; Su WY; Yan L; Sun JJ
    J Thromb Thrombolysis; 2019 Oct; 48(3):400-412. PubMed ID: 31062143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
    Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
    PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
    Kirkilesis GI; Kakkos SK; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
    Li A; Garcia DA; Lyman GH; Carrier M
    Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
    Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
    Patel A; Williams H; Baer MR; Zimrin AB; Law JY
    Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials.
    Sobieraj DM; Baker WL; Smith E; Sasiela K; Trexler SE; Kim O; Coleman CI
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):182S-187S. PubMed ID: 30244595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis.
    Zhou H; Ye LL; Zhou JT; Ma FX; Ma JJ; Zhang JH
    Surg Endosc; 2024 Mar; 38(3):1131-1138. PubMed ID: 38267639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials.
    Haykal T; Zayed Y; Deliwala S; Kerbage J; Ponnapalli A; Malladi S; Goranta S; Samji V; Adam S
    Thromb Res; 2020 Oct; 194():57-65. PubMed ID: 32788122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials.
    Elbadawi A; Shnoda M; Mahmoud K; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):380-388. PubMed ID: 32556105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.